Trial · NCT07894367
Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical Study
NCT07894367, Phase 2, Not yet recruiting, Peking University Cancer Hospital & Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical Study. Trials, record NCT07894367. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07894367
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical Study
- NCT number
- NCT07894367
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 23 participants, estimated
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Gematinib, Lenvatinib
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate（ORR） | From the time of the treatment until the disease progresses or a new anti-cancer treatment is initiated, the duration is up to 24 months | Percentage of patients achieving CR or PR per RECIST v1.1. |
| Secondary | Progression-Free Survival (PFS) | From the time of the first treatment until the disease progresses or the patient dies, whichever occurs first shall prevail up to 24 months. | Time from the start of randomization (or the start of treatment in a single-arm trial) to tumor progression or death from any cause, whichever occurs first. |
| Other | Disease control rate | From the time of the treatment until the disease progresses or a new anti-cancer treatment is initiated, the duration is up to 24 months | Percentage of patients achieving CR, PR, or SD per RECIST v1.1. |
| Other | The incidence rate of adverse events | From the beginning of the first treatment until 30 days after the last administration of the study treatment up to 24 months. | any adverse event that in the investigator's opinion may have been caused by the study medication with reasonable possibility per CTCAE 5.0. |
| Other | One-year overall survival rate | From the beginning of the treatment to the 12th month | The percentage of patients who survived for at least one year after the first administration of the drug |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07894367
GET https://conductscience.org/api/trials/v1/NCT07894367/registered